List of Tables
Table 3.1: Approved Gene Therapies Worldwide
Table 3.2: Key Companies in Cell and Gene Therapy Market, 2020
Table 4.1: Key Products of Cell and Gene Therapy Market
Table 8.1: Key Viral Vectors
Table 8.2: Cell and Gene Therapy Manufacturing Capacity (by Company)
Table 9.1: Number of Clinical Trials for Cell and Gene Therapy, 2020
Table 11.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
Table 11.2: Key Cell and Gene Therapy Drugs in Phase 3, 2020
Table 12.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA
List of Figures
Figure 1: Cell and Gene Therapy Funding (2019 and 2020-H1)
Figure 2: Global Cell and Gene Therapy Market, 2020-2027
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, January 2016-January 2021
Figure 5: Global Cell and Gene Therapy Market Share (Product Type), 2020-2027
Figure 6: Global Cell and Gene Therapy Market Share (by Therapeutic Class), 2020-2027
Figure 7: Global Cell and Gene Therapy Market (by Region)
Figure 1.1: Definitions of Cell and Gene Therapies
Figure 2.1: Global Cell and Gene Therapy Market Research Methodology
Figure 2.2: Primary Research Methodology
Figure 2.3: Global Cell and Gene Therapy Market Research Methodology Approach
Figure 2.4: Total Number of Companies Profiled
Figure 3.1: Clinical Trials by Therapeutic Category, Regenerative Medicines and Advanced Therapies, 2020
Figure 3.2: Global Cell and Gene Therapy Market Size, 2020-2027
Figure 3.3: Factors Involved in Payer Decision Flow, Process Considerations and Stakeholder Drivers in Reimbursement in U.S.
Figure 3.4: Emerging Payment Models for Cell and Gene Therapies in Europe
Figure 4.1: Addressable Market Size of Commercialized Products, 2020
Figure 4.2: Global Cell and Gene Therapy Market, 2020-2027
Figure 4.3: North America Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.4: Europe Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.6: Latin America Cell and Gene Therapy Addressable Market 2020 Vs 2027
Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Cell and Gene Therapy Market, 2020-2025
Figure 5.3: Areas of Disruption in Clinical Development
Figure 5.4: Measure to Navigate Crisis Recovery
Figure 6.1: Expedited Approval Designations for Cell and Gene Therapies
Figure 7.1: Number of Patents (by Year), 2016-2020
Figure 7.2: Share of Patents (by Country), 2016-2021
Figure 8.1: Steps Involved in Bioprocessing
Figure 8.2: Typical Production Methods of Viral Vectors
Figure 8.3: Typical Production Method of Plasmid Vectors
Figure 9.1: Impact Analysis of Market Dynamics
Figure 9.2: Rising Incidences of Cancer (2015 and 2018)
Figure 9.3: Prevalence of Rare Diseases
Figure 9.4: Deal Value of Mergers and Acquisitions (2016-2019)
Figure 10.1: Share of Key Developments and Strategies, January 2016- January 2021
Figure 10.2: Share of Product Offerings and Approvals, January 2016-January 2021
Figure 10.3: Share of Synergistic Activities, January 2016-January 2021
Figure 10.4: Share of Funding and Expansions, January 2016-January 2021
Figure 10.5: Share of Mergers and Acquisitions, January 2016-January 2021
Figure 10.6: Market Share Analysis: Global Cell and Gene Therapy Market, 2020
Figure 10.7: Growth-Share Matrix for Global Cell and Gene Therapy Market (by Company), 2020
Figure 11.1: Global Cell and Gene Therapy Market (by Therapeutic Drugs), 2020-2027
Figure 11.2: Global Revenue for Yescarta, 2020-2027
Figure 11.3: Global Revenue for Provenge, 2020-2027
Figure 11.4: Global Revenue for Luxturna, 2020-2027
Figure 11.5: Global Revenue for Kymriah, 2020-2027
Figure 11.6: Global Revenue for Imlygic, 2020-2027
Figure 11.7: Global Revenue for MACI, 2020-2027
Figure 11.8: Global Revenue for Gendicine, 2020-2027
Figure 11.9: Global Revenue for Oncorine, 2020-2027
Figure 11.10: Global Revenue for Neovasculogen, 2020-2027
Figure 11.11: Global Revenue for Strimvelis, 2020-2027
Figure 11.12: Global Revenue for Invossa, 2020-2027
Figure 11.13: Global Revenue for Zolgensma, 2020-2027
Figure 11.14: Global Revenue for Tecartus, 2020-2027
Figure 11.15: Global Revenue for Other Drugs, 2020-2027
Figure 11.16: Global Revenue for Other Drugs, 2020-2027
Figure 11.17: Global Revenue for Other Drugs, 2020-2027
Figure 11.18: Cell and Gene Therapy Medicines in Development by Disease, 2018
Figure 11.19: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2018-2020
Figure 11.20: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2018-2020
Figure 11.21: Global Cell and Gene Therapy Market, by Late Phase, 2021-2027
Figure 11.22: Global Revenue for SPK-8011, 2020-2027
Figure 11.23: Global Revenue for OTL-103, 2021-2027
Figure 11.24: Global Revenue for OTL-200, 2020-2027
Figure 11.25: Global Revenue for OTL-101, 2021-2027
Figure 11.26: Global Revenue for VM 202, 2021-2027
Figure 11.27: Global Revenue for GS010, 2021-2027
Figure 11.28: Global Revenue for bb2121, 2021-2027
Figure 11.29: Global Revenue for PTC-AADC, 2021-2027
Figure 11.30: Pipeline For CAR-T Therapies (2020)
Figure 12.1: Global Cell and Gene Therapy Market (Rare Diseases), 2020-2027
Figure 12.2: Global Cell and Gene Therapy Market (Oncology), 2020-2027
Figure 12.3: Global Cell and Gene Therapy Market (Hematology), 2020-2027
Figure 12.4: Global Cell and Gene Therapy Market (Cardiovascular Disease), 2020-2027
Figure 12.5: Global Cell and Gene Therapy Market (Ophthalmology), 2020-2027
Figure 12.6: Global Cell and Gene Therapy Market (Neurology), 2020-2027
Figure 12.7: Global Cell and Gene Therapy Market (Other Therapeutic Class), 2020-2027
Figure 12.8: Global Cell and Gene Therapy Market (by Region)
Figure 12.9: North America Global Cell and Gene Therapy Market, 2020-2027
Figure 12.10: North America: Market Dynamics
Figure 12.11: U.S. Cell and Gene Therapy Market, 2020-2027
Figure 12.12: Canada Cell and Gene Therapy Market, 2020-2027
Figure 12.13: Europe Cell and Gene Therapy Market, 2020-2027
Figure 12.14: Europe: Market Dynamics
Figure 12.15: Germany Cell and Gene Therapy Market, 2020-2027
Figure 12.16: France Cell and Gene Therapy Market, 2020-2027
Figure 12.17: U.K. Cell and Gene Therapy Market, 2020-2027
Figure 12.18: Italy Cell and Gene Therapy Market, 2020-2027
Figure 12.19: Spain Cell and Gene Therapy Market, 2020-2027
Figure 12.20 Netherlands Cell and Gene Therapy Market, 2020-2027
Figure 12.21: Russia Cell and Gene Therapy Market, 2020-2027
Figure 12.22: Rest-of-Europe Cell and Gene Therapy Market, 2020-2027
Figure 12.23: Asia-Pacific Cell and Gene Therapy Market, 2020-2027
Figure 12.24: Asia-Pacific Market Dynamics
Figure 12.25: Japan Cell and Gene Therapy Market, 2020-2027
Figure 12.26: China Cell and Gene Therapy Market, 2020-2027
Figure 12.27: Australia Cell and Gene Therapy Market, 2020-2027
Figure 12.28: South Korea Cell and Gene Therapy Market, 2020-2027
Figure 12.29: India Cell and Gene Therapy Market, 2020-2027
Figure 12.30: Singapore Cell and Gene Therapy Market, 2020-2027
Figure 12.31: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2020-2027
Figure 12.32: Latin America Cell and Gene Therapy Market, 2020-2027
Figure 12.33: Latin America: Market Dynamics
Figure 12.34: Brazil Cell and Gene Therapy Market, 2020-2027
Figure 12.35: Mexico Cell and Gene Therapy Market, 2020-2027
Figure 12.36: Rest-of-Latin America Cell and Gene Therapy Market, 2020-2027
Figure 12.37: Rest-of-World Cell and Gene Therapy Market, 2020-2027
Figure 13.1: Amgen Inc.: Overall Product Portfolio
Figure 13.2: Amgen Inc.: Pipeline Product Portfolio
Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
Figure 13.6: Amgen Inc.: SWOT Analysis
Figure 13.7: Pipeline Product Portfolio: bluebird bio, Inc.
Figure 13.8: bluebird bio, Inc.: Overall Financials, 2017-2019
Figure 13.9: bluebird bio, Inc.: R&D Expenditure, 2017-2019
Figure 13.10: bluebird bio, Inc.: SWOT Analysis
Figure 13.11: Dendreon Pharmaceuticals LLC: Product Portfolio
Figure 13.12: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 13.13: Castle Creek Pharmaceutical Holdings: Overall Product Portfolio
Figure 13.14: Castle Creek Pharmaceutical Holdings : Pipeline Product Portfolio
Figure 13.15: Castle Creek Pharmaceutical: SWOT Analysis
Figure 13.16: Human Stem Cell Institute: Overall Product Portfolio
Figure 13.17: Human Stem Cell Institute: SWOT Analysis
Figure 13.18: Kite Pharma, Inc.: Overall Product Portfolio
Figure 13.19: Kite Pharma, Inc.: Pipeline Product Portfolio
Figure 13.20: Kite Pharma, Inc.: Overall Financials, 2016-2018
Figure 13.21: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
Figure 13.22: Kite Pharma, Inc.: SWOT Analysis
Figure 13.23: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 13.24: Kolon TissueGene, Inc.: SWOT Analysis
Figure 13.25: Novartis AG: Overall Product Portfolio
Figure 13.26: Novartis AG: Pipeline Product Portfolio
Figure 13.27: Novartis AG: Overall Financials, 2017-2019
Figure 13.28: Novartis AG: Revenue (by Business Segment), 2017-2019
Figure 13.29: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.30: Novartis AG: R& D Expense, 2017-2019
Figure 13.31: Novartis AG: SWOT Analysis
Figure 13.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 13.33: Orchard Therapeutics plc.: Overall Financials, 2017-2019
Figure 13.34: Orchard Therapeutics plc: SWOT Analysis
Figure 13.35: Organogenesis Holdings Inc.: Overall Product Portfolio
Figure 13.36: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
Figure 13.37: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
Figure 13.38: Organogenesis Holdings Inc.: SWOT Analysis
Figure 13.39: Pfizer, Inc.: Overall Product Portfolio
Figure 13.40: Pfizer, Inc.: Pipeline Product Portfolio
Figure 13.41: Pfizer, Inc.: Overall Financials, 2017-2019
Figure 13.42: Pfizer, Inc.: Revenue (by Region), 2017-2019
Figure 13.43: Pfizer, Inc.: R&D Expenditure, 2017-2019
Figure 13.44: Pfizer, Inc.: SWOT Analysis
Figure 13.45: RENOVA THERAPEUTICS: Pipeline Product Portfolio
Figure 13.46: RENOVA THERAPEUTICS: SWOT Analysis
Figure 13.47: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 13.48: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 13.49: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
Figure 13.50: Sibiono GeneTech Co. Ltd.: SWOT Analysis
Figure 13.51: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 13.52: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 13.53: Spark Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 13.54: Spark Therapeutics, Inc.: R&D Expenditure, 2017-2019
Figure 13.55: Spark Therapeutics, Inc.: SWOT Analysis
Figure 13.56: Vericel Corporation: Overall Product Portfolio
Figure 13.57: Vericel Corporation: Overall Financials, 2017-2019
Figure 13.58: Vericel Corporation: Revenue (by Product), 2017-2019
Figure 13.59: Vericel Corporation: R&D Expenditure (2017-2019)
Figure 13.60: Vericel Corporation: SWOT Analysis